Nonhormonal Menopause Treatments

Which nonhormonal menopause treatments have useful evidence?

For troublesome hot flashes and night sweats, useful options include menopause-specific cognitive behavioral therapy (CBT), selected SSRI or SNRI antidepressants, gabapentin and neurokinin-targeting medicines. The best choice depends on the symptom you want to change, why HRT is unsuitable or unwanted, other medicines and the follow-up you can obtain. “Nonhormonal” does not mean mild, natural or free of adverse effects. [1], [2], [4]–[8]

These options can be appropriate when a person cannot use HRT, prefers another treatment, or needs additional help under a clinical plan. HRT remains the most effective established treatment for vasomotor symptoms when suitable. Declining it does not mean declining care. Conversely, a personal preference should be revisited if it arose from an inaccurate description of risk; the discussion should compare your actual options rather than a reassuring label on one category. [1]–[3]

First separate vasomotor symptoms from vaginal or urinary symptoms, depression, persistent insomnia and other medical problems. A hot-flash medicine does not replace estrogen for every purpose. Vaginal moisturizers and lubricants serve a local comfort goal; they do not reduce night sweats. A new symptom, substantial change or unexplained bleeding still needs assessment instead of being assigned automatically to menopause. [2]

Which decision comes before choosing a treatment?

An ordinary consultation should identify one or two important goals and the unwanted effects you most need to avoid. Driving, shift work, constipation, other sedating medicines, liver history and the ability to attend laboratory checks can change the practical choice. These are reasons to personalize selection, not to label an entire medicine class universally safer. [4]–[8]

Ask what benefit would justify continuing and when to review it. A medicine can reduce episodes without solving vaginal dryness, while CBT can make symptoms less disruptive without a clear reduction in frequency. Discuss access and the exact ongoing cost with the local service or pharmacist; authorization and a guideline recommendation do not prove local stock or your coverage. [3], [9], [10]

How do the main medicine options differ?

Fezolinetant targets neurokinin-3 signaling involved in temperature regulation. The current US Veozah label has a boxed warning for hepatotoxicity: liver testing before treatment, monthly for the first three months, then at months six and nine. It also contraindicates CYP1A2 inhibitors and specified liver/renal conditions. Possible liver-injury symptoms require stopping and immediate medical contact for testing. A symptom improvement does not remove that plan. [4]

Elinzanetant targets neurokinin-1 and neurokinin-3 receptors. Its current US Lynkuet label requires liver tests before treatment and at month three, with additional evaluation for relevant symptoms or findings. That is not the Veozah schedule. Somnolence and other CNS effects matter for driving, and the label includes seizure precautions. The reviewed UK Lynkuet authorization also covers vasomotor symptoms caused by adjuvant endocrine therapy for breast cancer; the US indication reviewed here is menopause-related vasomotor symptoms. The UK liver-monitoring wording differs too. [5], [6]

Selected SSRIs and SNRIs can reduce vasomotor symptoms even when depression is not the indication. A particular antidepressant can nevertheless have separate psychiatric uses, doses and precautions. Brisdelle is a US paroxetine product labeled for menopausal vasomotor symptoms, not treatment of a psychiatric condition. Review serotonergic medicines, MAOIs, discontinuation effects and sexual adverse effects. Paroxetine inhibits CYP2D6 and can reduce formation of tamoxifen’s active metabolite; the prescriber should consider alternatives rather than treating that as a routine compatible pairing. [1], [7]

Gabapentin has evidence for vasomotor symptoms but that indication is off-label in the reviewed US Neurontin label. Dizziness and sedation can outweigh benefit for some people. Kidney function changes dosing, and concomitant opioids or other CNS depressants can increase respiratory-depression risk. The US label describes withdrawal over at least one week when reducing, discontinuing or substituting, with longer plans at clinical discretion. This is not a universal online taper; prior use and symptoms can require an individualized approach. [1], [8]

Oxybutynin has supporting vasomotor evidence in the 2023 statement, but anticholinergic effects such as dry mouth and constipation, along with cognitive concerns particularly in older adults, require consideration. Clinical hypnosis is another evidence-supported non-drug option, but a trained service matters. Clonidine and pregabalin were not recommended as vasomotor treatments in that statement. An existing prescription may have a different licensed indication; do not stop it merely because its menopause evidence is weaker. [1]

Why do guidelines make different recommendations?

The Menopause Society’s 2023 statement recommends CBT, clinical hypnosis, selected SSRIs/SNRIs, gabapentin and fezolinetant on Level I evidence, with other options receiving different evidence levels. Its purpose is to identify effective nonhormonal vasomotor treatments. It predates elinzanetant approval, so the absence of Lynkuet from that document is not a negative assessment of a later medicine. [1]

Current NICE NG23 recommends HRT for vasomotor symptoms when appropriate, menopause-specific CBT in specified circumstances, and fezolinetant when HRT is unsuitable through TA1143. It does not routinely offer SSRIs, SNRIs or clonidine as first-line treatment for vasomotor symptoms alone. That recommendation does not say selected antidepressants never work. It addresses routine first-line positioning within a broader care pathway; a separate depression indication also changes the decision. [2], [3]

NICE’s fezolinetant appraisal notes that direct comparisons with established nonhormonal medicines are unavailable and that indirect comparisons are uncertain. A clinician should not turn separate trial averages into a proven head-to-head ranking. The choice still needs the exact contraindications, interaction review, acceptable harms and access. [3]

What do the studies actually measure?

DAYLIGHT randomized 453 participants aged 40–65 who were considered unsuitable for hormone therapy to fezolinetant 45 mg daily or placebo for twenty-four weeks. Unsuitability included contraindication, caution, previous discontinuation and preference; it was not an exclusively cancer-survivor trial. At week twenty-four, the adjusted between-group difference in moderate/severe vasomotor frequency was −1.93 episodes per day (95% CI −2.64 to −1.22). That is an average additional reduction relative to placebo, not the percentage of participants cured. The population was 96.7% White, and caution/preference groups predominated. [9]

MENOS 1 randomized 96 women with troublesome symptoms after breast-cancer treatment: 47 to group CBT and 49 to usual care. Six weekly sessions each lasted ninety minutes. The primary outcome was a 1–10 hot-flash/night-sweat problem rating. At nine weeks, the adjusted between-group difference was −1.67 points (95% CI −2.43 to −0.91); at twenty-six weeks, −1.76 (−2.54 to −0.99). The study did not find a significant between-group difference in episode frequency, and its prespecified two-point primary between-group difference was not achieved. Symptom burden still improved. [10]

These results are useful precisely because they measure different things. A frequency outcome and a problem rating cannot be compared by their numerical size. Nor can a trial in a general hormone-therapy-unsuitable population establish the same result in every endocrine-therapy or cancer context. Ask whether the study’s population and endpoint match your goal, and whether the uncertainty would change the choice. [9], [10]

What about vaginal symptoms, exercise and supplements?

Vaginal moisturizers used for ongoing dryness and lubricants used to reduce friction are nonhormonal local options. NICE recommends them when vaginal estrogen is contraindicated or declined, and as an initial option after breast cancer. Persistent symptoms can justify discussion of other treatment, including local vaginal estrogen in an individualized plan; people taking an aromatase inhibitor need coordination with the cancer specialist. Local estrogen is hormonal, even when systemic exposure is low. [2]

Vaginal laser should not be offered outside a randomized trial under NICE’s recommendation. Pain, recurring urinary problems and bleeding are reasons to reassess the diagnosis rather than endlessly adding comfort products. [2]

Exercise, comfortable clothing, cooling and an enjoyable food routine can improve general health or comfort. The 2023 statement did not recommend exercise, yoga, cooling, trigger avoidance, dietary modification, acupuncture or supplements/herbal remedies as established vasomotor therapies because evidence was insufficient or inconsistent. That is not a verdict that comfort habits are pointless. It is a reason not to promise reliable hot-flash control or to blame someone when symptoms persist. “Natural” products can also interact with prescribed medicines. [1]

Which precautions should change the plan?

A complete medicine list is more useful than the broad label “nonhormonal.” Include cancer endocrine therapy, antidepressants, opioids, sleeping medicines and supplements. Review liver and kidney history, driving demands, mood symptoms and past withdrawal problems. The pharmacist can check the exact combination; a reminder app cannot establish interaction safety. [4]–[8]

With fezolinetant, new unusual fatigue, nausea, itching, jaundice, dark urine, pale stools or abdominal pain can signal liver injury: stop and seek immediate medical contact for testing under the US label. The US Lynkuet label also requires immediate stopping and medical attention, including liver tests, for symptoms suggesting liver injury. Elinzanetant can also impair alertness. Severe breathing difficulty, a seizure, serious allergic symptoms or a mental-health crisis need urgent assessment rather than waiting to see whether a diary improves. Exact medicine instructions and local emergency advice govern the response. [4], [5], [8]

Planned stopping also differs. Antidepressant and gabapentin discontinuation can require a gradual, individualized approach; a daily reminder does not imply safe abrupt cessation. Ask about the stop plan before starting, especially if previous withdrawal was difficult. If HRT is being replaced, keep its separate vaginal, bone or hormone-deficiency goals visible. Switching a symptom treatment should not accidentally remove needed care for another condition. [1], [2], [7], [8]

What do public experiences help readers ask?

A selected public discussion about gabapentin versus HRT describes conflicting advice about treatment choice. Comments include symptom or sleep benefit, incomplete relief, dizziness, cognitive complaints and difficult stopping. These themes support questions about the actual target, daily functioning, tolerability and a stop plan. They do not establish how often benefit or harm occurs. [11]

The discussion also contains strong cancer and dementia assertions and instructions to favor one treatment. Those statements are not validated by the thread. Bring a concrete concern to the clinician rather than a forum’s categorical verdict; a personal account can explain what matters to a reader without establishing causation or the safest prescription. [11]

A second public discussion focused on nonhormonal medicines includes benefit, partial or absent response, sleepiness, stopping concerns and cost difficulties. Readers sometimes assess sleep or the distress preceding a flash rather than frequency alone. These themes help define a useful follow-up question; they do not supply a product ranking or a dose to reproduce. [12]

How can you tell whether the plan is helping?

Agree on a small set of outcomes before a change: episodes per day, nights interrupted, interference at work or a symptom-burden rating. Use the same definitions at follow-up. Add unwanted effects that matter, such as next-day sleepiness or constipation, and note the actual medicine and start/change dates. A sparse consistent record is often more useful than an elaborate daily score that is abandoned. [2], [9], [10]

Do not treat a personal rating as a validated clinical scale or proof of medicine causation. Record whether the change was worthwhile in your own life, while separating a simultaneous new medicine, illness or schedule change. Laboratory monitoring remains the prescriber’s plan; recording a reminder does not mean a blood test was ordered, completed or interpreted. [4], [5]

At follow-up ask: Has the target improved enough? Are adverse effects acceptable? Were required checks completed? Is another symptom now the main problem? An ineffective treatment deserves review rather than indefinite escalation. A useful treatment can still need adjustment if an interaction, medical history or practical access changes. [2], [4]–[8]

Common questions

Are these treatments as effective as HRT?

HRT remains the most effective established vasomotor treatment when suitable, but several nonhormonal options can provide meaningful relief. There is no reliable universal ranking built from unrelated trial averages. NICE notes uncertainty in indirect comparisons of fezolinetant with established nonhormonal medicines. Choose the treatment around your actual goal, precautions and access, then reassess whether the benefit is worthwhile. See the guideline comparison and the study endpoints. [1]–[3]

Does CBT mean the symptoms are imaginary?

No. Menopause-specific CBT addresses how symptoms affect sleep, distress and daily life; it does not deny the underlying physiological change. MENOS 1 found improvement in problem ratings after breast-cancer treatment without a significant between-group frequency difference. That is a useful but distinct outcome. A clinician can discuss CBT alongside medication or when HRT is unsuitable or declined. Persistent symptoms still deserve care. See the CBT evidence and the goal table. [2], [10]

Do all neurokinin medicines need the same liver tests?

No. The current US Veozah label calls for baseline testing, monthly testing for the first three months and further testing at months six and nine. The current US Lynkuet label calls for baseline and month-three testing, with additional evaluation when indicated. UK Lynkuet wording also differs. Check the exact product, country and current label rather than using a class schedule. Symptoms suggesting liver injury require prompt action regardless of a planned test date. See the medicine comparison. [4]–[6]

Can I use paroxetine while taking tamoxifen?

This pairing needs a prescriber or oncology-pharmacist review. Paroxetine inhibits CYP2D6 and can reduce formation of tamoxifen’s active metabolite; the Brisdelle label advises considering alternatives. A drug being nonhormonal does not make it automatically compatible with cancer treatment. Do not stop tamoxifen or an antidepressant on your own to resolve the question. Bring the exact products and indications so the team can choose an appropriate alternative. See the interaction discussion. [7]

Can I stop gabapentin when symptoms improve?

Agree on a stopping plan with the prescriber. The reviewed US label describes gradual withdrawal over at least one week when reducing, discontinuing or substituting, with longer plans at clinical discretion. Actual exposure, indication and withdrawal history can change the plan. That minimum is not a personalized taper instruction, and another country’s current wording may differ. Improvement does not prove abrupt stopping will be comfortable or safe. See the stopping precautions and gabapentin’s distinct role. [8]

Will a nonhormonal hot-flash treatment protect my bones?

Do not assume so. Vasomotor relief is a symptom outcome; it does not supply estrogen replacement or establish fracture prevention. Bone risk and early ovarian hormone loss require a separate assessment and plan. Vaginal symptoms and contraception also remain separate goals. If replacing HRT with a nonhormonal medicine, ask which other reasons for HRT still need care rather than judging the switch only by fewer sweats. See the decision table. [1], [2]

Are cooling, exercise and supplements worth trying?

Comfort habits and exercise can support wellbeing and general health, but they should not be promised as established vasomotor treatments. The 2023 statement found insufficient or inconsistent evidence for many lifestyle and complementary approaches specifically for hot flashes. A cooling strategy that helps you feel comfortable can still be useful; persistent symptoms are not a failure of effort. Supplements also need an ingredient and interaction review rather than automatic reassurance from “natural.” See comfort measures and evidence limits. [1]

Glossary

Terms for comparing the evidence and practical choices.

Vasomotor symptoms

Hot flashes and night sweats.

Cognitive behavioral therapy

A structured psychological approach; menopause-specific programs address symptom burden, beliefs, sleep and coping.

Clinical hypnosis

A therapeutic method delivered by a trained clinician, distinct from entertainment hypnosis.

SSRI

Selective serotonin reuptake inhibitor, a medicine class with product-specific indications and interactions.

SNRI

Serotonin-norepinephrine reuptake inhibitor; selected products have vasomotor evidence.

Neurokinin

A signaling peptide; particular receptors are targeted by newer vasomotor medicines.

Anticholinergic

Blocking certain acetylcholine actions, with possible dry mouth, constipation and cognitive effects.

Central nervous system

The brain and spinal cord; medicines can affect alertness or breathing through CNS effects.

Sedation

Reduced alertness or sleepiness that can affect driving and daily functioning.

Hepatotoxicity

A medicine-related potential for liver injury.

CYP1A2

An enzyme relevant to fezolinetant metabolism and interactions.

CYP2D6

An enzyme important for forming tamoxifen’s active metabolite; paroxetine inhibits it.

Contraindication

A circumstance in which the product should not be used according to its label.

Off-label use

Use outside a specific product’s authorized indication, population or instructions.

Placebo

A comparator without the trial’s active treatment; symptom changes can occur in its group too.

Confidence interval

A range expressing statistical uncertainty around an estimated effect, not individual variation.

Endpoint

The outcome measured in a study, such as episode frequency or problem rating.

Problem rating

A measure of how troublesome symptoms feel; it is distinct from episode frequency.

Genitourinary syndrome of menopause

Menopause-related genital and urinary changes, including dryness, discomfort and some urinary symptoms.

Vaginal moisturizer

A nonhormonal local product used to improve ongoing vaginal comfort and dryness.

Lubricant

A product reducing friction, distinct from ongoing treatment of tissue changes.

Aromatase inhibitor

A medicine that reduces estrogen production, often part of breast-cancer endocrine therapy.

Discontinuation effects

Symptoms associated with reducing or stopping certain medicines; they do not automatically mean the original condition returned.

Endometrium

The uterine lining; nonhormonal vasomotor medicines do not provide progestogen protection for systemic estrogen.

How was this guide researched?

We reviewed the complete 2023 nonhormone position statement, current NICE recommendations and final TA1143 recommendation, current US medicine labels, the UK Lynkuet SmPC and complete DAYLIGHT and MENOS 1 original reports. Product monitoring is taken from the current label rather than inferred from a drug class or a trial protocol. [1]–[10]

The source directory identifies the reviewed material and its limits. Trial endpoints retain population, comparator and follow-up. Public discussion text and selected comments were retrieved for practical questions; they are not a systematic collection or response-rate estimate. This guide does not claim current pharmacy stock or individual reimbursement. [11]

How this guide was made

We distinguish complete labels, guidelines, original studies and selected public accounts. Clinical claims retain their population, route and jurisdiction; forum accounts supply questions rather than prescribing instructions. Choices are explained without turning trial averages into individual promises.

Explore the sources